ClinicalTrials.gg
RecruitingNCT07873450Updated Nov 16, 2026

SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

A Phase 1/2 interventional study of [225Ac]Ac-FL-261 and [225Ac]Ac-FL-261 in Solid Tumor, NSCLC and Colorectal Cancer, sponsored by Full-Life Technologies UK Limited. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Full-Life Technologies UK Limited · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Now RecruitingFirst sites in Australia, United States and China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
510th of 1,932
208 · median 64
Started
2026
with 117 others
Phase 1/2
266 of 2,339
68 open now
Primary completion
2030-06
later than 588 of 628 live
Registered
2,328th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 510th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 266 in phase 1/2, reaches primary completion later than 588 of the 628 other live ones, and was the 2,328th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose through dose escalation, followed by a randomized comparison of two candidate dosing regimens (dose optimization). In Phase 2, the selected dose will be tested in independent cohorts by tumor type.

Read the detailed description

Phase 1: Dose Escalation

[225Ac]Ac-FL-261 will be administered at increasing doses in participants with non-squamous non-small cell lung cancer (ns-NSCLC) to identify the maximum tolerated dose (MTD) based on a BOIN design.

Phase 1 - Dose Optimization

After Dose Escalation is complete, 2 treatment regimens will be compared to select the optimal treatment regimen (OTR) between them.

Phase2

Participants with ns-NSCLC, colorectal cancer, head and neck cancer and cholangiocarcinoma will be enrolled into separate cohorts to estimate the efficacy of [225Ac]Ac-FL-261 at the OTR in each indication.

03

Conditions studied

  • Solid Tumor
  • NSCLC
  • Colorectal Cancer
  • Head and Neck Cancer
  • Cholangiocarcinoma

Keywords

  • Non small cell lung cancer
  • metastatic NSCLC
  • advanced NSCLC
  • H&N cancer
  • bile duct cancers
  • CRC
  • Phase 1
  • dose escalation
  • dose optimization
  • phase 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • They have signed the consent form before any study-related tests or procedures are done and are willing to follow all study requirements.
  • They are 18 years of age or older.
  • They have a confirmed diagnosis of an advanced or cancer that cannot be cured with surgery, radiation, or other treatments.
  • Phase 1: Non-squamous non-small cell lung cancer (ns-NSCLC).
  • Phase 2: Non-squamous non-small cell lung cancer (ns-NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), or cholangiocarcinoma (bile duct cancer).
  • Their cancer has worsened after previous treatments, or they cannot receive further standard treatments because of reasons such as side effects or medical conditions.
  • For lung cancer (ns-NSCLC): Previously treated with chemotherapy, immunotherapy, and targeted therapies if applicable.
  • For colorectal cancer (CRC): Previously treated with standard chemotherapy and other suitable targeted or immune therapies if specific genetic changes were present.
  • For head and neck cancer (HNSCC): Previously treated with platinum-based chemotherapy and immunotherapy.
  • For cholangiocarcinoma: Previously treated with at least one chemotherapy regimen.
  • The cancer must be c-MET positive, meaning laboratory testing of the tumor shows a moderate to high level of c-MET protein in at least half of the cancer cells.
  • At least one tumor can be measured on scans according to standard cancer assessment criteria.
  • The participant is generally well enough for daily activities, with an Performance Status of 0 or 1 (fully active or only restricted in strenuous activities).
  • Important organs are functioning adequately, based on blood and laboratory test results, including:
  • Normal heart rhythm measurement ().
  • Women who can become pregnant must have a negative pregnancy test during screening and again shortly before starting study treatment.
  • Women who can become pregnant must use an effective method from the first dose of study treatment until 6 months after the last dose.
  • Sexually active men must use a barrier method of contraception (such as condoms) during the study and for about 3 months after the last dose. They must also not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  • Cancer has spread to the brain or spinal cord and has not been treated.
  • People with previously treated may still be eligible if they are stable, have no symptoms, and are not taking for neurological problems.
  • They have a serious medical or mental health condition that could make participation unsafe or affect the study results.
  • They have previously received radioactive cancer treatments, such as radioembolization (for example, Y-90 treatment).
  • They received anti-cancer treatment within the last 4 weeks before starting the study drug.

They received an experimental () anti-cancer treatment within the last 4 weeks or within 5 half-lives of that treatment (whichever period is longer).

  • They received radiation therapy too recently, including:

    • Radiation to a large area of bone marrow within 6 weeks before study treatment, or
    • Radiation to a specific area within 2 weeks before study treatment.
  • They had major surgery within the last 6 weeks or have not completely recovered from the surgery and its side effects.
  • They are allergic to the study drug or any of its ingredients.
  • They are currently participating in another clinical trial that involves treatment or intervention.
  • They still have significant side effects from previous cancer treatments.

    • People may still be eligible if they have:
    • Hair loss of any severity,
    • Mild to moderate nerve damage (Grade 2),
    • Moderate fatigue (Grade 2),
    • Stable diabetes,
    • Well-controlled underactive or overactive thyroid disease.
  • They have a history of interstitial lung disease (a serious lung condition that causes scarring and inflammation of the lungs).
  • They have serious heart disease, including:

    • Heart attack within the last 6 months,
    • Unstable chest pain (angina),
    • Moderate to severe heart failure,
    • Uncontrolled high blood pressure,
    • Uncontrolled abnormal heart rhythms,
    • Severe narrowing of the aortic heart valve.
  • They have an active infection that requires treatment, including:

    • ,
    • ,
    • ,
    • COVID-19 (SARS-CoV-2).

However, some people with chronic HIV, hepatitis B, or hepatitis C may be allowed to participate if their infection is well controlled and approved by the study doctor.

  • They have had another type of active cancer within the last 3 years, apart from the cancer being studied.

    • Some exceptions may be allowed if the other cancer is well controlled and does not require treatment during the study.
  • They are pregnant or breastfeeding, or plan to become pregnant or donate eggs during the study or within 6 months after the last dose of the study drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Phase 1 - Dose Escalation

    Dose escalation will use the Bayesian Optimal Interval (BOIN) design to determine the maximum tolerated dose (MTD).

    Drug: [225Ac]Ac-FL-261

  • Experimental
    Phase 1 - Dose Optimization

    Randomized comparison of two candidate dosing regimens to select the optimal treatment regimen (OTR) for Phase 2.

    Drug: [225Ac]Ac-FL-261

  • Experimental
    Phase 2

    The optimal dose and regimen is tested in separate cohorts by tumor type, using a two-stage design.

    Drug: [225Ac]Ac-FL-261

Interventions

  • Dose escalation per BOIN design to determine MTD.

  • Two candidate dosing regimens, randomized 1:1 (30 participants per arm)

  • * Non-squamous non-small cell lung cancer (NSCLC) * Colorectal cancer (CRC) * Head and neck squamous cell carcinoma (HNSCC) * Cholangiocarcinoma

06

What researchers measure

Primary outcomes

  1. Phase 1 Dose Escalation: Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: Until 28 days after the first injection of [225Ac]Ac-FL-261]

  2. 2. Phase 1 Dose Escalation and Phase 1 Dose Optimization: Type, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0

    Time frame: From ICF signature and up to 35 days after the last dose of study treatment for all AEs/SAEs. Thereafter, only AEs of special interest (AESIs) and related SAEs will be reported (up to 5 years)

  3. Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 5 years)

Secondary outcomes

  1. Phase 1 and Phase 2: Duration of response (DoR)

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)

  2. Phase 1 and Phase 2: Disease control rate (DCR)

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)]

  3. Phase 1 and Phase 2: Progression-free survival (PFS) by RECIST v1.1

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)

  4. Phase 1 and Phase 2: Overall survival (OS)

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)

  5. Phase 1: ORR by RECIST v1.1

    Time frame: Every 6 weeks for 24 weeks, then every 12 weeks, until disease progression (up to 5 years)

  6. Phase 1 and Phase 2: Peak plasma concentration (Cmax) of [225Ac]Ac-FL-261

    Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2 (each cycle is 28 days); and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1

  7. Phase 1 and Phase 2: Time to achieve Cmax (tmax)

    Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2; and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1

  8. Phase 1 and Phase 2: Area under the plasma concentration-time curve (AUC)

    Time frame: Phase 1: Up to Day 15 of Cycle 1 and Cycle 2; and on the first day of Cycle 3 and Cycle 4. Phase 2: Up to Day 15 of Cycle 1

  9. Phase 2: Type, frequency, and severity of AEs and SAEs using NCI CTCAE v6.0.

    Time frame: From ICF signature and up to 35 days after the last dose of study treatment for all AEs/SAEs. Thereafter, only AESIs and related SAEs will be reported (up to 5 years)

07

Study locations

3 of 3 sites recruiting
  • Full-Life Technologies Investigational Site
    Minneapolis, Minnesota 55414, United States
    Recruiting
  • Full-Life Technologies Investigational Site
    Nedlands, Australia
    Recruiting
  • Full-Life Technologies Investigational Site
    Beijing, China
    Recruiting
08

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 42 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 14, 2026
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
3 sites added — first sites in Australia, United States and China
Show 3 added (1 Australia, 1 United States, 1 China)
  • Full-Life Technologies Investigational Site · Nedlands, Australia
  • Full-Life Technologies Investigational Site · Minneapolis, United States
  • Full-Life Technologies Investigational Site · Beijing, China
across 3 updates, Oct 16, 2026 – Nov 16, 2026
Start date
Oct 1, 2026→Dec 1, 2026
Nov 16, 2026
Registered
First appeared on the registry
Oct 14, 2026
Show all 4 updates
  1. Nov 16, 2026
    1 site added — first site in China
    Show site
    • Full-Life Technologies Investigational Site · Beijing, China
    Start date Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date
  2. Oct 29, 2026
    1 site added — first site in United States
    Show site
    • Full-Life Technologies Investigational Site · Minneapolis, United States
    + 1 other change: verification date
  3. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • Full-Life Technologies Investigational Site · Nedlands, Australia
  4. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873450
Lead sponsor
Full-Life Technologies UK Limited
Responsible party
Sponsor
First posted
Oct 14, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Full-Life Technologies
Contact
clinicaltrials@t-full.com
617-939-7858

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion